1. Sulfasalazine is a prodrug in which 5-aminosalicylic acid (5-ASA, the active anti-inflammatory moiety, also called mesalamine) is joined to a carrier molecule by an azo bond. In a patient with ulcerative colitis taking sulfasalazine, which event is required for the active anti-inflammatory drug to be released at the site of mucosal inflammation?
A) Acetylation of the parent compound by hepatic N-acetyltransferase in the liver
B) Hydrolysis of an ester linkage by pancreatic esterases in the duodenum
C) Cleavage of the azo bond by bacterial azo-reductase enzymes in the colon
D) Oxidation of the parent compound by intestinal cytochrome P450 3A4 (CYP3A4)
E) Spontaneous dissolution of an enteric polymer coating at gastric pH
ANSWER: C
Rationale:
Sulfasalazine consists of 5-ASA (mesalamine, the active moiety) linked to sulfapyridine (a sulfonamide carrier) by an azo bond. The bond resists absorption in the upper gut, so the intact prodrug travels to the distal small intestine and colon, where colonic bacteria expressing azo-reductase enzymes cleave the bond and release mesalamine locally at the inflamed mucosa. Because the active drug is liberated by bacterial action in the colon, delivery is targeted to the site of disease with minimal systemic exposure of the active moiety.
Option A: Option A is incorrect: acetylation by hepatic N-acetyltransferase is the metabolic fate of the released sulfapyridine carrier (slow acetylators accumulate more sulfapyridine and have more adverse effects), not the activation step that releases the anti-inflammatory drug.
Option B: Option B is incorrect: sulfasalazine contains an azo bond, not an ester linkage, and pancreatic esterases are not the activating enzymes.
Option D: Option D is incorrect: CYP3A4 oxidation is not the mechanism that liberates 5-ASA from sulfasalazine; oxidative hepatic metabolism characterizes drugs such as budesonide, not the azo-bond cleavage of sulfasalazine.
Option E: Option E is incorrect: sulfasalazine activation depends on bacterial azo-reductase, not on dissolution of a pH-dependent enteric coating; pH-dependent coatings are a separate delivery strategy used by certain sulfa-free mesalamine formulations.
2. A 28-year-old woman with mild ulcerative colitis is started on sulfasalazine. Her clinician adds a daily folic acid supplement and counsels her about the drug's adverse effects. Most of sulfasalazine's adverse effects, and the need for folic acid supplementation, are attributable to which component of the molecule?
A) The sulfapyridine carrier moiety
B) The 5-aminosalicylic acid (5-ASA) active moiety
C) The azo bond linking the two components
D) An inert ethylcellulose microsphere coating
E) A multi-matrix (MMX) hydrophilic-lipophilic excipient
ANSWER: A
Rationale:
In sulfasalazine, therapeutic activity resides almost entirely in the 5-ASA (mesalamine) moiety, while the sulfapyridine carrier is responsible for most of the drug's adverse effects. Sulfapyridine is absorbed systemically after bacterial cleavage and is acetylated in the liver; slow acetylators accumulate higher concentrations and experience more toxicity. Sulfapyridine-related effects include nausea, headache, reversible oligospermia, hemolytic anemia in glucose-6-phosphate dehydrogenase (G6PD) deficiency, and rare immune-mediated reactions such as agranulocytosis. Critically, sulfapyridine competitively inhibits intestinal folate absorption, which is why all patients on sulfasalazine should receive folic acid 1 mg daily—especially women of childbearing potential, in whom folate deficiency carries neural tube defect risk.
Option B: Option B is incorrect: the 5-ASA moiety is the therapeutically active anti-inflammatory component and is comparatively well tolerated; sulfa-free 5-ASA formulations were specifically developed to avoid sulfapyridine toxicity.
Option C: Option C is incorrect: the azo bond is simply the chemical linkage cleaved by colonic bacteria and is not itself a source of systemic toxicity or folate malabsorption.
Option D: Option D is incorrect: ethylcellulose microsphere coatings are a delivery feature of certain mesalamine products (for example, controlled-release granules), not a component of sulfasalazine, and are pharmacologically inert.
Option E: Option E is incorrect: the MMX multi-matrix excipient is a delivery technology used in once-daily mesalamine tablets, not a constituent of sulfasalazine, and does not account for its adverse effects.
3. Mesalamine (5-aminosalicylic acid) exerts its therapeutic effect topically on the bowel mucosa rather than through systemic immunosuppression. Which description best characterizes the principal mechanism by which mesalamine reduces mucosal inflammation in ulcerative colitis?
A) Binding of a glucocorticoid-receptor complex to glucocorticoid response elements to induce anti-inflammatory gene transcription
B) Inhibition of dihydrofolate reductase, depleting tetrahydrofolate needed for purine and thymidylate synthesis
C) Incorporation of active thioguanine nucleotides into lymphocyte DNA, terminating cell proliferation
D) Local inhibition of cyclo-oxygenase (COX) and suppression of nuclear factor kappa B (NF-kB) signaling in mucosal cells
E) Neutralization of circulating tumor necrosis factor-alpha (TNF-alpha) by a monoclonal antibody
ANSWER: D
Rationale:
Mesalamine acts locally at the bowel mucosa through several overlapping anti-inflammatory actions. It inhibits cyclo-oxygenase (COX), reducing prostaglandin and thromboxane synthesis, and suppresses activation of the transcription factor NF-kB (nuclear factor kappa-light-chain-enhancer of activated B cells) in epithelial and immune cells, lowering production of pro-inflammatory cytokines such as interleukin-1, interleukin-6, and TNF-alpha. It also scavenges reactive oxygen species generated by mucosal neutrophils and macrophages. The net result is attenuation of the mucosal inflammatory cascade without the systemic immunosuppression that accompanies corticosteroids or immunomodulators.
Option A: Option A is incorrect: glucocorticoid-receptor binding to glucocorticoid response elements is the genomic mechanism of corticosteroids, not of 5-ASA agents.
Option B: Option B is incorrect: dihydrofolate reductase inhibition is the classic mechanism of methotrexate, not mesalamine.
Option C: Option C is incorrect: incorporation of thioguanine nucleotides into DNA is the mechanism of the thiopurines azathioprine and 6-mercaptopurine, not of 5-ASA.
Option E: Option E is incorrect: TNF-alpha neutralization describes anti-TNF biologics such as infliximab and adalimumab, which act systemically rather than as topical mucosal agents.
4. A patient with mild to moderate left-sided ulcerative colitis has only a partial response to oral mesalamine alone. According to current guideline-based practice, what is the most appropriate next step before escalating to corticosteroids or immunomodulators?
A) Switch from oral mesalamine to oral sulfasalazine at an equivalent dose
B) Add rectal mesalamine (enema) to the existing oral mesalamine therapy
C) Begin maintenance oral prednisone at a low daily dose
D) Start azathioprine immediately for rapid induction of remission
E) Replace mesalamine with oral budesonide controlled-ileal-release capsules
ANSWER: B
Rationale:
For left-sided and extensive ulcerative colitis (UC), combining oral mesalamine with rectal mesalamine produces higher mucosal drug concentrations throughout the affected colon, faster symptomatic response, and superior endoscopic remission rates compared with oral therapy alone. Guidelines recommend this combination as first-line for mild to moderate active UC; an enema targets the left colon to the splenic flexure, while a suppository is used for proctitis. A patient with an inadequate response to oral 5-ASA should therefore have rectal therapy added before stepping up to systemic agents.
Option A: Option A is incorrect: substituting sulfasalazine offers no mechanistic advantage over mesalamine for efficacy and adds sulfapyridine-related toxicity; it does not represent guideline-directed escalation.
Option C: Option C is incorrect: corticosteroids have no role in UC maintenance—they do not alter disease natural history and carry cumulative toxicity—so initiating maintenance prednisone is inappropriate.
Option D: Option D is incorrect: thiopurines take 3 to 6 months to reach therapeutic effect and cannot induce remission rapidly; jumping to azathioprine bypasses the simpler, more effective optimization of topical 5-ASA.
Option E: Option E is incorrect: ileal-release budesonide is formulated for ileocecal Crohn's disease and is released proximal to the left colon, making it a poor choice for left-sided UC and not the appropriate next step here.
5. Before initiating sulfasalazine in a patient with ulcerative colitis, which screening test is most important to obtain in order to avoid a specific drug-induced hematologic complication caused by the sulfapyridine component?
A) Baseline thiopurine S-methyltransferase (TPMT) enzyme activity assay
B) Baseline serum 6-thioguanine nucleotide (6-TGN) concentration
C) Baseline liver transient elastography (Fibroscan) for hepatic fibrosis
D) Baseline anti-drug antibody titer against the sulfonamide carrier
The sulfapyridine carrier in sulfasalazine can precipitate hemolytic anemia in patients with glucose-6-phosphate dehydrogenase (G6PD) deficiency, an enzyme defect that leaves red cells vulnerable to oxidative stress. Screening for G6PD deficiency before starting sulfasalazine identifies at-risk patients, in whom sulfapyridine-free mesalamine formulations are preferred.
Option A: Option A is incorrect: TPMT activity testing is required before thiopurines (azathioprine, 6-mercaptopurine) to predict myelosuppression risk, not before sulfasalazine.
Option B: Option B is incorrect: 6-TGN levels are a therapeutic-monitoring tool for thiopurine therapy and have no role in sulfasalazine initiation.
Option C: Option C is incorrect: hepatic fibrosis monitoring with transient elastography is relevant to long-term methotrexate therapy, not to the hemolytic risk posed by sulfapyridine.
Option D: Option D is incorrect: anti-drug antibody monitoring applies to biologic agents (for example, infliximab immunogenicity), not to sulfasalazine, and would not detect the oxidative hemolysis risk that G6PD screening addresses.
6. A patient with Crohn's disease has required two courses of prednisone in the past year and flares each time the dose is tapered below 15 mg daily. Which statement best reflects the correct role of corticosteroids in this situation?
A) Corticosteroids are effective for inducing remission but have no role in maintenance, and steroid dependence is an indication to escalate to an immunomodulator or biologic
B) Corticosteroids should be continued indefinitely at the lowest dose that prevents relapse, as they favorably alter the natural history of the disease
C) Corticosteroids are an appropriate long-term maintenance therapy provided liver function tests remain normal
D) Corticosteroids should be replaced by oral mesalamine, which has equivalent efficacy for maintaining Crohn's disease remission
E) Corticosteroids prevent post-operative recurrence of Crohn's disease and should be continued for that purpose
ANSWER: A
Rationale:
Corticosteroids are potent inducers of remission in both ulcerative colitis and Crohn's disease, acting through genomic suppression of pro-inflammatory gene transcription. However, they have no role in maintenance: they do not alter disease natural history, do not prevent relapse, and carry cumulative toxicity (for example, bone loss, glucose intolerance, and hypothalamic-pituitary-adrenal axis suppression) that makes chronic use unacceptable. A patient who needs steroids more than once per year or cannot taper off without relapse meets the definition of steroid-dependent disease and should be escalated to an immunomodulator (such as a thiopurine or methotrexate) or a biologic.
Option B: Option B is incorrect: corticosteroids do not favorably alter natural history, and indefinite use is precisely what should be avoided.
Option C: Option C is incorrect: normal liver tests do not make chronic steroid maintenance acceptable; the limiting toxicities are systemic and cumulative, independent of hepatic function.
Option D: Option D is incorrect: mesalamine has weak and unproven efficacy for Crohn's disease maintenance and is not an equivalent substitute.
Option E: Option E is incorrect: corticosteroids do not prevent post-operative recurrence of Crohn's disease and are not used for that indication.
7. Oral budesonide controlled-ileal-release is preferred over systemic prednisone for mild to moderate ileocecal Crohn's disease because it causes fewer systemic corticosteroid adverse effects. What is the pharmacokinetic basis for budesonide's reduced systemic toxicity?
A) Budesonide is not absorbed from the gastrointestinal tract and acts only within the bowel lumen
B) Budesonide binds the glucocorticoid receptor with much lower affinity than prednisone
C) Budesonide undergoes extensive first-pass hepatic metabolism by CYP3A4, giving an oral systemic bioavailability of only about 10 to 15 percent
D) Budesonide is rapidly eliminated unchanged by the kidney before reaching the systemic circulation
E) Budesonide is a prodrug that is activated only by colonic bacterial enzymes
ANSWER: C
Rationale:
Budesonide is a synthetic glucocorticoid with high topical anti-inflammatory potency that is well absorbed but then undergoes extensive first-pass metabolism in the liver, predominantly by CYP3A4 (cytochrome P450 3A4). This results in an oral systemic bioavailability of only about 10 to 15 percent, compared with roughly 80 to 100 percent for prednisone. The low systemic exposure substantially reduces hypothalamic-pituitary-adrenal axis suppression, Cushingoid features, bone mineral density loss, and glucose intolerance, although these effects are not entirely absent with prolonged use. Because budesonide is a CYP3A4 substrate, strong CYP3A4 inhibitors (azole antifungals, macrolides, certain protease inhibitors) can markedly raise systemic exposure.
Option A: Option A is incorrect: budesonide is in fact absorbed; its safety advantage comes from hepatic first-pass clearance after absorption, not from a lack of absorption.
Option B: Option B is incorrect: budesonide has high, not low, glucocorticoid receptor affinity—its topical potency is greater than that of prednisone.
Option D: Option D is incorrect: budesonide is cleared by hepatic metabolism, not by rapid renal elimination of unchanged drug.
Option E: Option E is incorrect: budesonide is not a bacterially activated prodrug; its controlled-release formulation simply targets luminal delivery, and the bioavailability advantage is a first-pass metabolic phenomenon.
8. A patient hospitalized with severe acute ulcerative colitis is started on intravenous methylprednisolone. By day 3, validated clinical indices show no meaningful response. What is the most appropriate next management step?
A) Continue intravenous corticosteroids unchanged for at least 14 more days
B) Initiate rescue therapy with infliximab or intravenous cyclosporine
C) Switch to oral mesalamine and discharge the patient on maintenance therapy
D) Begin azathioprine monotherapy to induce remission over the next several days
E) Add adrenocorticotropic hormone (ACTH) to stimulate endogenous cortisol output
ANSWER: B
Rationale:
In severe acute ulcerative colitis, response to intravenous corticosteroids should be assessed formally around day 3. Patients who fail to respond should be moved to rescue therapy—intravenous cyclosporine or infliximab—rather than continuing steroids beyond about 5 to 7 days without response, because prolonging ineffective steroids delays definitive treatment and raises the risk of complications. Roughly 30 to 40 percent of patients with severe acute disease ultimately require colectomy if rescue therapy also fails.
Option A: Option A is incorrect: continuing unchanged intravenous steroids for an extended period in a non-responder is exactly what should be avoided.
Option C: Option C is incorrect: a patient with steroid-refractory severe disease cannot be safely stepped down to oral mesalamine and discharged; this would undertreat a potentially life-threatening flare.
Option D: Option D is incorrect: thiopurines take months to reach therapeutic effect and cannot induce remission in an acute severe flare.
Option E: Option E is incorrect: ACTH has been largely abandoned in favor of direct corticosteroid administration and does not constitute appropriate rescue therapy for steroid-refractory severe colitis.
9. Azathioprine is a thiopurine prodrug used for maintenance of remission in inflammatory bowel disease. Which sequence correctly describes its activation and the metabolic branch point that generates the active immunosuppressive metabolites?
A) Azathioprine is oxidized by xanthine oxidase directly to 6-thioguanine nucleotides, the active metabolites
B) Azathioprine is methylated by thiopurine S-methyltransferase to 6-thioguanine nucleotides, the active metabolites
C) Azathioprine is acetylated in the liver to 6-mercaptopurine, which is then renally excreted unchanged
D) Azathioprine is non-enzymatically converted to 6-mercaptopurine, which is then anabolized by hypoxanthine-guanine phosphoribosyltransferase (HPRT) to active 6-thioguanine nucleotides
E) Azathioprine is cleaved by colonic bacterial azo-reductase to release the active 6-thioguanine nucleotides locally
ANSWER: D
Rationale:
Azathioprine (AZA) is non-enzymatically cleaved in erythrocytes and intestinal cells to 6-mercaptopurine (6-MP). 6-MP then enters three competing pathways: the anabolic pathway catalyzed by hypoxanthine-guanine phosphoribosyltransferase (HPRT) produces 6-thioguanine nucleotides (6-TGN), the active immunosuppressive metabolites that are incorporated into dividing lymphocyte DNA to terminate proliferation and induce apoptosis; the catabolic pathway via xanthine oxidase (XO) produces inactive 6-thiouric acid; and the pathway via thiopurine S-methyltransferase (TPMT) produces inactive 6-methylmercaptopurine (6-MMP), which is associated with hepatotoxicity at high levels.
Option A: Option A is incorrect: xanthine oxidase catabolizes 6-MP to an inactive metabolite (6-thiouric acid); it does not generate the active 6-TGN.
Option B: Option B is incorrect: TPMT methylation produces inactive 6-MMP, not the active 6-TGN.
Option C: Option C is incorrect: azathioprine is converted to 6-MP non-enzymatically rather than by hepatic acetylation, and 6-MP is metabolized rather than renally excreted unchanged.
Option E: Option E is incorrect: azo-reductase cleavage describes activation of 5-ASA prodrugs such as sulfasalazine, not the conversion of azathioprine.
10. Genotyping identifies a patient as a thiopurine S-methyltransferase (TPMT) poor metabolizer (two non-functional alleles) before starting azathioprine. If a standard dose were given without adjustment, what is the expected consequence and the reason for it?
A) Therapeutic failure, because all 6-mercaptopurine is shunted to inactive 6-thiouric acid by xanthine oxidase
B) Hepatotoxicity only, because excess drug is diverted entirely into 6-methylmercaptopurine formation
C) No clinical change, because TPMT activity does not influence thiopurine metabolite levels
D) Accelerated drug clearance, because poor metabolizers eliminate 6-mercaptopurine more rapidly
E) Severe, potentially life-threatening myelosuppression, because loss of the methylation pathway channels 6-mercaptopurine into the HPRT pathway, generating very high 6-thioguanine nucleotide levels
ANSWER: E
Rationale:
In a TPMT (thiopurine S-methyltransferase) poor metabolizer, the methylation pathway that normally diverts 6-mercaptopurine (6-MP) toward inactive 6-methylmercaptopurine is essentially absent. As a result, 6-MP is channeled into the anabolic HPRT (hypoxanthine-guanine phosphoribosyltransferase) pathway, generating extremely high concentrations of active 6-thioguanine nucleotides (6-TGN). At standard doses this produces severe, potentially life-threatening myelosuppression. For this reason, TPMT phenotyping or genotyping before starting azathioprine or 6-MP is mandatory: poor metabolizers require dose reduction to roughly 10 percent of standard or should avoid thiopurines, and intermediate metabolizers need roughly 30 to 50 percent dose reduction.
Option A: Option A is incorrect: loss of methylation increases 6-TGN rather than shunting drug toward inactive thiouric acid, so the result is toxicity, not therapeutic failure.
Option B: Option B is incorrect: the methylation pathway is the one that is lost, so 6-MMP formation falls rather than rises; the dominant hazard is myelosuppression from high 6-TGN.
Option C: Option C is incorrect: TPMT activity strongly influences metabolite distribution and is a major determinant of myelotoxicity.
Option D: Option D is incorrect: poor metabolizers do not clear the drug faster; functionally they accumulate more active metabolite.
11. A patient of East Asian ancestry is being evaluated for thiopurine therapy. A normal TPMT result alone is considered insufficient to predict myelotoxicity risk in this patient. Which additional pharmacogenomic test is recommended, and why?
A) CYP3A4 genotyping, because thiopurines are activated by hepatic CYP3A4 oxidation
B) NUDT15 genotyping, because loss-of-function variants allow thioguanine triphosphates to accumulate and cause myelosuppression independent of TPMT, and these variants are more frequent in East Asian populations
C) G6PD screening, because thiopurines cause oxidative hemolysis in deficient patients
D) UGT1A1 genotyping, because thiopurines are cleared by glucuronidation
E) HLA-B*57:01 typing, because thiopurines cause a hypersensitivity reaction in carriers
ANSWER: B
Rationale:
NUDT15 (nudix hydrolase 15) encodes a diphosphatase that inactivates thiopurine triphosphate metabolites. Loss-of-function NUDT15 variants allow thioguanine triphosphates to accumulate in leukocytes and cause myelosuppression even when TPMT activity is normal—so NUDT15 is a TPMT-independent predictor of thiopurine myelotoxicity. The NUDT15 R139C variant is far more common in East Asian populations (allele frequency around 10 percent) than in Europeans (under 0.2 percent), which is why pre-treatment NUDT15 genotyping is recommended, particularly for patients of East Asian ancestry. Current guidance recommends testing both TPMT and NUDT15 before initiating a thiopurine.
Option A: Option A is incorrect: thiopurines are not activated by CYP3A4 oxidation, and CYP3A4 genotyping does not predict their myelotoxicity.
Option C: Option C is incorrect: G6PD screening addresses oxidative hemolysis with sulfapyridine-containing sulfasalazine, not thiopurine myelosuppression.
Option D: Option D is incorrect: UGT1A1 glucuronidation status is relevant to drugs such as irinotecan, not to thiopurine myelotoxicity.
Option E: Option E is incorrect: HLA-B*57:01 typing predicts abacavir hypersensitivity, not thiopurine-induced bone marrow suppression.
12. A patient stable on full-dose azathioprine for Crohn's disease is about to be started on allopurinol for newly diagnosed gout. Why is co-prescribing allopurinol at this point potentially dangerous, and what is the correct principle?
A) Allopurinol inhibits xanthine oxidase, blocking the catabolic pathway and shifting 6-mercaptopurine toward 6-thioguanine nucleotide accumulation, which can cause fatal myelosuppression unless the azathioprine dose is markedly reduced
B) Allopurinol induces thiopurine S-methyltransferase, accelerating azathioprine clearance and causing loss of disease control
C) Allopurinol displaces azathioprine from plasma protein binding sites, transiently raising free drug without clinical consequence
D) Allopurinol and azathioprine have no clinically significant interaction and may be co-prescribed at full doses
E) Allopurinol chelates azathioprine in the gut lumen, preventing its absorption and causing therapeutic failure
ANSWER: A
Rationale:
Allopurinol inhibits xanthine oxidase (XO), the enzyme that catabolizes 6-mercaptopurine (6-MP) to inactive 6-thiouric acid. When allopurinol is added to full-dose azathioprine (AZA) or 6-MP, the blocked catabolic pathway diverts 6-MP toward the anabolic pathway, producing a large increase in active 6-thioguanine nucleotides (6-TGN) and risking fatal myelosuppression. The combination is used intentionally in IBD as a rescue strategy for the preferential-methylation pattern (high 6-MMP, low 6-TGN), but only with immediate reduction of the AZA dose to roughly 25 to 33 percent of the original and intensified blood count monitoring. Adding allopurinol to full-dose thiopurine without dose reduction is a potentially lethal error.
Option B: Option B is incorrect: allopurinol does not induce TPMT or accelerate thiopurine clearance; it blocks catabolism and raises active metabolite levels.
Option C: Option C is incorrect: the interaction is a metabolic one with major clinical consequence, not a benign protein-binding displacement.
Option D: Option D is incorrect: the interaction is clinically significant and dangerous at full doses—the opposite of no interaction.
Option E: Option E is incorrect: allopurinol does not chelate azathioprine or block its absorption; the hazard is excess active metabolite, not therapeutic failure.
13. A patient with newly diagnosed, actively flaring Crohn's disease is started on azathioprine alone, with no other agent added. Why is this an inadequate treatment plan for the active flare?
A) Azathioprine is contraindicated in Crohn's disease and is approved only for ulcerative colitis
B) Azathioprine is an induction-only agent and will lose efficacy if continued beyond the flare
C) Therapeutic 6-thioguanine nucleotide accumulation takes 3 to 6 months, so a thiopurine cannot induce remission rapidly and active disease must be bridged with a corticosteroid or biologic
D) Azathioprine works within 24 to 48 hours, so the only error is failing to give an intravenous loading dose
E) Azathioprine should always be combined with methotrexate to achieve rapid induction
ANSWER: C
Rationale:
Thiopurines act as steroid-sparing maintenance agents, not induction agents. Because therapeutic accumulation of active 6-thioguanine nucleotides takes about 3 to 6 months after starting azathioprine or 6-mercaptopurine, a thiopurine cannot control an active flare quickly. Active disease therefore must be bridged with a faster-acting agent—typically a corticosteroid or a biologic—while the thiopurine is co-initiated for long-term maintenance. Starting a thiopurine alone in active disease leaves the patient effectively untreated during the months-long onset period.
Option A: Option A is incorrect: thiopurines are used in both Crohn's disease and ulcerative colitis; they are not contraindicated in Crohn's.
Option B: Option B is incorrect: thiopurines are maintenance agents, the opposite of induction-only, and do not lose efficacy when appropriately continued.
Option D: Option D is incorrect: thiopurines have a delayed onset of months, not hours, and there is no rapid intravenous loading strategy that overcomes this.
Option E: Option E is incorrect: combining azathioprine with methotrexate is not standard and does not produce rapid induction; bridging is achieved with steroids or a biologic.
14. In the SONIC trial framework, azathioprine is combined with an anti-tumor necrosis factor (anti-TNF) biologic such as infliximab in Crohn's disease. Beyond additive anti-inflammatory effect, what is a key pharmacological rationale for combining a thiopurine with the biologic?
A) The thiopurine accelerates hepatic clearance of the biologic, preventing drug accumulation
B) The thiopurine converts the biologic into its active form within the gut mucosa
C) The thiopurine allows the biologic to be dosed once yearly rather than at regular intervals
D) The thiopurine eliminates the need for any infection screening before biologic therapy
E) The thiopurine reduces formation of anti-drug antibodies against the biologic, improving and prolonging its efficacy
ANSWER: E
Rationale:
Combining azathioprine (AZA) with an anti-TNF biologic (infliximab or adalimumab) reduces the formation of anti-drug antibodies directed against the biologic. Lower immunogenicity preserves therapeutic drug levels and prolongs efficacy, and combination therapy proved more effective than either agent alone for induction and maintenance of remission in Crohn's disease in the SONIC trial. The tradeoff is increased risk of opportunistic infection (for example, Pneumocystis jirovecii pneumonia and herpes zoster), so vaccination and prophylaxis decisions should be reviewed.
Option A: Option A is incorrect: the benefit is reduced immunogenicity, not accelerated clearance of the biologic.
Option B: Option B is incorrect: anti-TNF biologics are administered as active monoclonal antibodies and are not activated by thiopurines.
Option C: Option C is incorrect: combination therapy does not convert the biologic to once-yearly dosing; scheduled maintenance dosing is still required.
Option D: Option D is incorrect: combination immunosuppression increases infection risk and makes pre-treatment screening more, not less, important.
15. At the once-weekly low doses used for inflammatory bowel disease (15 to 25 mg), methotrexate's anti-inflammatory effect is largely attributable to a mechanism distinct from its classic cytotoxic action. Which mechanism predominates at these immunomodulatory doses?
A) Direct neutralization of tumor necrosis factor-alpha by the drug molecule
B) Irreversible inhibition of colonic cyclo-oxygenase, reducing mucosal prostaglandins
C) Incorporation of methotrexate into lymphocyte DNA, halting replication like a thiopurine
D) Accumulation of methotrexate polyglutamates that inhibit AICAR transformylase, increasing extracellular adenosine, which suppresses immune-cell function
E) Binding of a glucocorticoid-receptor complex to glucocorticoid response elements
ANSWER: D
Rationale:
Methotrexate's classic action is inhibition of dihydrofolate reductase, depleting tetrahydrofolate needed for purine and thymidylate synthesis—the basis of its cytotoxic, high-dose effects. At the low weekly doses used in IBD, however, the predominant anti-inflammatory mechanism is intracellular accumulation of methotrexate polyglutamates, which inhibit the enzyme AICAR (5-aminoimidazole-4-carboxamide ribonucleotide) transformylase. This raises extracellular adenosine, which acts on adenosine receptors of immune cells to suppress cytokine production, T-cell proliferation, and neutrophil function. This adenosine-mediated effect operates at doses that do not cause overt cytotoxicity.
Option A: Option A is incorrect: methotrexate does not directly bind or neutralize TNF-alpha; that is the action of anti-TNF biologics.
Option B: Option B is incorrect: mesalamine, not methotrexate, works through mucosal COX inhibition.
Option C: Option C is incorrect: incorporation into DNA to halt replication describes thiopurine active metabolites, not methotrexate's low-dose anti-inflammatory mechanism.
Option E: Option E is incorrect: glucocorticoid-receptor binding to response elements is the corticosteroid mechanism, unrelated to methotrexate.
16. For maintenance of remission in Crohn's disease, methotrexate is usually given by subcutaneous or intramuscular injection rather than orally. What is the pharmacokinetic basis for preferring the parenteral route at the doses used in IBD?
A) Oral methotrexate is destroyed by gastric acid and must bypass the stomach entirely
B) Oral methotrexate has variable bioavailability because intestinal absorption via the folate carrier is saturable and declines at doses above about 15 mg, so parenteral dosing gives reliable systemic exposure
C) Parenteral methotrexate is required because the oral form is not approved for human use
D) Oral methotrexate undergoes near-complete first-pass hepatic inactivation, leaving no active drug
E) Parenteral administration is needed because methotrexate cannot cross any cell membrane when taken orally
ANSWER: B
Rationale:
Oral methotrexate bioavailability is highly variable (roughly 25 to 100 percent) because absorption occurs via a saturable folate carrier transporter (the reduced folate carrier), and bioavailability falls substantially at doses above about 15 mg. Parenteral administration (subcutaneous or intramuscular) bypasses this saturable intestinal step and provides reliable, consistently high systemic exposure at the 15 to 25 mg weekly doses used in Crohn's disease.
Option A: Option A is incorrect: the limitation is saturable carrier-mediated absorption, not gastric acid destruction.
Option C: Option C is incorrect: oral methotrexate is an approved formulation; the issue is pharmacokinetic reliability, not lack of approval.
Option D: Option D is incorrect: oral methotrexate is not subject to near-complete first-pass hepatic inactivation; the variability arises at the absorption step.
Option E: Option E is incorrect: methotrexate is transported into cells by carrier mechanisms regardless of route, so the parenteral preference reflects absorption reliability, not an inability to cross membranes.
17. A 26-year-old woman with Crohn's disease who hopes to conceive within the next year is being considered for a steroid-sparing immunomodulator. Which statement about methotrexate is correct and most relevant to this decision?
A) Methotrexate is absolutely contraindicated in pregnancy because it is teratogenic and abortifacient, so reliable contraception is mandatory during therapy and it must be discontinued well before planned conception
B) Methotrexate is the preferred immunomodulator in women planning pregnancy because it is safe in all trimesters
C) Methotrexate may be continued through conception as long as folic acid supplementation is given
D) Methotrexate poses no reproductive risk and requires no contraception counseling
E) Methotrexate is contraindicated only in the third trimester and may be used freely before then
ANSWER: A
Rationale:
Methotrexate is absolutely contraindicated in pregnancy: it is teratogenic and abortifacient, inhibiting trophoblast proliferation and fetal folate metabolism, and has caused spontaneous abortion, fetal death, and major congenital malformations at therapeutic doses. Reliable contraception is mandatory during therapy, and the drug must be discontinued well before planned conception (generally at least 3 months beforehand). In a woman of reproductive age intending to conceive, this strongly influences immunomodulator choice and warrants explicit family-planning discussion at initiation and at every renewal.
Option B: Option B is incorrect: methotrexate is not safe in pregnancy and is not preferred for women planning conception.
Option C: Option C is incorrect: folic acid supplementation reduces certain mucosal and hematologic side effects but does not make methotrexate safe to continue through conception.
Option D: Option D is incorrect: methotrexate carries major reproductive risk and absolutely requires contraception counseling.
Option E: Option E is incorrect: the contraindication is not limited to the third trimester; methotrexate is hazardous throughout pregnancy and around conception.
18. A patient on long-term methotrexate for Crohn's disease is being monitored for the drug's most important chronic organ toxicity. Which adverse effect and monitoring strategy are correctly paired?
A) Nephrotoxicity, monitored with weekly 24-hour urine protein collections
B) Pulmonary fibrosis, monitored with monthly spirometry as the primary surveillance tool
C) Hepatotoxicity (dose-dependent hepatic fibrosis), monitored with baseline and periodic (every 4 to 8 weeks) ALT and AST measurements
D) Cardiotoxicity, monitored with serial echocardiography every 4 weeks
E) Ototoxicity, monitored with quarterly audiometry
ANSWER: C
Rationale:
The most important chronic adverse effect of methotrexate in IBD is hepatotoxicity, specifically dose-dependent hepatic fibrosis, with risk rising with cumulative dose and with cofactors such as obesity, type 2 diabetes, and alcohol use. Monitoring uses liver function tests—alanine aminotransferase (ALT) and aspartate aminotransferase (AST)—at baseline and every 4 to 8 weeks during therapy; persistent elevations above twice the upper limit of normal prompt dose reduction, and persistent elevation despite reduction warrants discontinuation and hepatology referral. Non-invasive fibrosis tools (transient elastography, FIB-4 index) are increasingly used.
Option A: Option A is incorrect: although methotrexate is renally eliminated and accumulates in renal impairment, dose-dependent hepatic fibrosis—not a primary nephrotoxicity monitored by weekly urine protein—is the central chronic concern.
Option B: Option B is incorrect: methotrexate can cause pneumonitis, but routine monthly spirometry is not the primary surveillance strategy, and the dominant chronic toxicity is hepatic.
Option D: Option D is incorrect: cardiotoxicity with serial echocardiography is not a recognized methotrexate monitoring pathway.
Option E: Option E is incorrect: ototoxicity is not a characteristic methotrexate toxicity and audiometry is not part of monitoring.
19. All patients on methotrexate for IBD should receive folic acid supplementation. Why does folic acid reduce methotrexate's adverse effects without diminishing its anti-inflammatory efficacy?
A) Folic acid neutralizes methotrexate in the bloodstream, lowering total drug exposure uniformly
B) Folic acid converts methotrexate into an inactive metabolite that is then renally cleared
C) Folic acid blocks intestinal absorption of methotrexate, reducing both efficacy and toxicity equally
D) Folic acid has no real effect on methotrexate toxicity and is given only by convention
E) The adverse effects (mucositis, nausea, cytopenias) arise from dihydrofolate reductase inhibition in rapidly dividing tissues, which folate repletion mitigates, whereas the anti-inflammatory effect is adenosine-mediated and folate-independent
ANSWER: E
Rationale:
Many of methotrexate's troublesome side effects—mucositis, nausea, alopecia, and cytopenias—arise from inhibition of dihydrofolate reductase in rapidly dividing non-immune tissues. Supplemental folic acid (commonly 1 mg daily or 5 mg weekly on a non-methotrexate day) replenishes folate in these tissues and reduces those toxicities. Crucially, the low-dose anti-inflammatory effect operates through the adenosine pathway rather than through folate antagonism, so folate repletion does not blunt efficacy.
Option A: Option A is incorrect: folic acid does not neutralize circulating methotrexate or uniformly lower exposure; it repletes the folate pool in affected tissues.
Option B: Option B is incorrect: folic acid does not chemically convert methotrexate into an inactive metabolite.
Option C: Option C is incorrect: folic acid does not block methotrexate absorption, and if it reduced efficacy equally the supplementation strategy would be self-defeating—efficacy is preserved precisely because it is folate-independent.
Option D: Option D is incorrect: folic acid meaningfully reduces methotrexate toxicity and is given for that reason, not merely by convention.
20. When choosing between methotrexate and a thiopurine for steroid-sparing maintenance, disease type and patient sex influence the decision. Which statement correctly reflects the comparative positioning of these agents?
A) Methotrexate is the preferred maintenance immunomodulator for ulcerative colitis, with thiopurines reserved for Crohn's disease only
B) Methotrexate and thiopurines are interchangeable in all settings, with no role for disease type or sex in the choice
C) Thiopurines are contraindicated in Crohn's disease, leaving methotrexate as the only maintenance option
D) Thiopurines are preferred for ulcerative colitis maintenance because methotrexate lacks proven efficacy in UC, while in Crohn's disease both are acceptable and methotrexate is often favored in men due to the higher thiopurine-associated lymphoma risk in that group
E) Methotrexate is preferred in women of reproductive age because of its favorable pregnancy profile
ANSWER: D
Rationale:
Methotrexate's efficacy differs sharply by disease type. Randomized trials show no benefit over placebo for ulcerative colitis maintenance, so thiopurines are the preferred immunomodulator in UC. In Crohn's disease, methotrexate and thiopurines have comparable efficacy as monotherapy steroid-sparing agents, and the choice is shaped by TPMT and NUDT15 status, tolerability, reproductive plans, and sex—methotrexate is often favored in men with Crohn's disease because it avoids the thiopurine-associated non-Hodgkin lymphoma risk that is higher in men.
Option A: Option A is incorrect: it reverses the evidence; methotrexate is the weaker agent in UC, not the preferred one.
Option B: Option B is incorrect: disease type and sex clearly influence the choice, so the agents are not freely interchangeable.
Option C: Option C is incorrect: thiopurines are not contraindicated in Crohn's disease; they are a standard maintenance option there.
Option E: Option E is incorrect: methotrexate is teratogenic and is therefore less preferred—not preferred—in women of reproductive age.
21. A clinician is planning long-term therapy for a patient with moderately active Crohn's disease who will be started on a slow-onset immunomodulator. Which principle correctly integrates induction and maintenance for both methotrexate and thiopurines?
A) Neither methotrexate nor a thiopurine induces remission rapidly, so active disease must be bridged with a corticosteroid or biologic while the maintenance agent reaches full effect over weeks to months
B) Both methotrexate and thiopurines induce remission within 48 hours, so no bridging agent is ever required
C) Corticosteroids should be continued indefinitely alongside the immunomodulator as permanent maintenance
D) The immunomodulator should be withheld until the patient has been in steroid-free remission for one year
E) Methotrexate induces remission rapidly while thiopurines do not, so only thiopurine starts require bridging
ANSWER: A
Rationale:
Both thiopurines and methotrexate are maintenance agents with delayed onset—thiopurines take roughly 3 to 6 months for therapeutic 6-thioguanine nucleotide accumulation, and low-dose methotrexate likewise builds its anti-inflammatory effect over weeks. Because neither controls an active flare quickly, active disease must be bridged with a faster-acting agent (corticosteroid or biologic) while the maintenance immunomodulator is co-initiated and reaches full effect. Once remission is achieved, the bridging steroid is tapered off, since steroids have no maintenance role.
Option B: Option B is incorrect: neither agent acts within 48 hours; both have delayed onset and routinely require bridging in active disease.
Option C: Option C is incorrect: corticosteroids must not be used as permanent maintenance because of cumulative toxicity and lack of disease-modifying benefit.
Option D: Option D is incorrect: withholding the maintenance agent until a year of steroid-free remission defeats the purpose of co-initiating it as a bridge-and-maintain strategy.
Option E: Option E is incorrect: methotrexate does not induce remission rapidly; both agents are slow in onset, so bridging applies to both, not to thiopurines alone.
22. Before initiating any thiopurine for IBD maintenance, a safety-focused pre-treatment workup is required. Which approach correctly summarizes the pharmacogenomic testing principle and its consequence for drug selection?
A) Test TPMT only; NUDT15 status is irrelevant to thiopurine safety in all populations
B) Test both TPMT and NUDT15 before starting a thiopurine; poor metabolizers (TPMT) and homozygous loss-of-function (NUDT15) patients require major dose reduction or selection of an alternative agent such as methotrexate
C) No pre-treatment testing is needed because myelosuppression cannot occur in patients with normal genotypes
D) Test NUDT15 only, since TPMT status does not affect 6-thioguanine nucleotide accumulation
E) Begin full-dose thiopurine first and order pharmacogenomic testing only if cytopenias develop
ANSWER: B
Rationale:
Current guidance is to test both TPMT (thiopurine S-methyltransferase) and NUDT15 (nudix hydrolase 15) before initiating a thiopurine, because each independently predicts myelotoxicity. TPMT poor metabolizers and NUDT15 homozygous loss-of-function patients accumulate dangerously high active metabolites and require major dose reduction or an alternative agent such as methotrexate; intermediate phenotypes need moderate dose reduction with close monitoring.
Option A: Option A is incorrect: NUDT15 is a clinically important, TPMT-independent predictor, especially in East Asian populations, so testing TPMT alone is insufficient.
Option C: Option C is incorrect: myelosuppression can still occur in patients with normal genotypes, which is why ongoing blood-count monitoring continues regardless of testing results.
Option D: Option D is incorrect: TPMT status strongly affects metabolite distribution and 6-thioguanine nucleotide accumulation, so NUDT15 alone is inadequate.
Option E: Option E is incorrect: starting full-dose thiopurine before testing exposes poor metabolizers to life-threatening myelosuppression; testing is done before initiation, not after toxicity appears.
This Web-based pharmacology and disease-based integrated teaching site is based on reference materials that are believed reliable and consistent with standards accepted at the time of development.
Possibility of error and on-going research and development in medical sciences do not allow assurance that the information contained herein is in every respect accurate or complete.
Users should confirm the information contained herein with other sources.
This site should only be considered as a teaching aid for undergraduate and graduate biomedical education and is intended only as a teaching site.
Information contained here should not be used for patient management and should not be used as a substitute for consultation with practicing medical professionals.
Users of this website should check the product information sheet included in the package of any drug they plan to administer to be certain that the information contained in this site is accurate and that changes have not been made in the recommended dose or in the contraindications for administration.
Medical or other information thus obtained should not be used as a substitute for consultation with practicing medical or scientific or other professionals.